at Zacks.com (Tue, 6:50PM)
Sanofi (SNY -2%) and Regeneron (REGN -2.5%) today announce that they are enrolling patients in more than 10 late-stage clinical trials , named Odyssey, for a potentially first-in-class cholesterol - lowering drug targeting an enzyme called PCSK9. Odyssey will involve more than 22K patients, including 18K in a trial to measure cardiovascular outcomes such as heart attacks and strokes.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 23, 2015)
at Zacks.com (Jan 20, 2015)
at Benzinga.com (Jan 15, 2015)
at Zacks.com (Jan 13, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs